FDA Tweaks Med Device Standards List, Ho Hum
Published Date: 3/20/2025
Notice
Summary
The FDA just updated its official list of standards that medical device makers can use to prove their products are safe and effective. These changes take effect on March 20, 2025, helping companies speed up their approval process without extra costs. If you’re in the medical device world, this means clearer rules and smoother reviews starting soon!
Analyzed Economic Effects
3 provisions identified: 2 benefits, 0 costs, 1 mixed.
FDA updates recognized standards list
The FDA published modifications to its list of recognized consensus standards that manufacturers may use to meet parts of medical device premarket review submissions. These modifications are applicable March 20, 2025, and the FDA says the publication will assist manufacturers who elect to declare conformity with consensus standards.
Many standards withdrawn and replaced
The notice lists the withdrawal and replacement of multiple previously recognized consensus standards across device areas (for example, Anesthesiology, Cardiovascular, Materials, Radiology, Orthopedic, and others). These withdrawals and replacements are incorporated into Recognition List Number: 063 and are applicable March 20, 2025.
FDA adds new recognized standards
Table 2 of the notice adds new consensus standards to the FDA Recognized Consensus Standards list (Recognition List Number: 063). New entries include standards in areas such as Anesthesiology (e.g., ISO 4135), Orthopedic, Radiology, Software/Health informatics (ISO/IEEE 11073-10701), sterility, and others; these additions are part of the modifications applicable March 20, 2025.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2025-04710, Revocation of Three Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availability
The FDA is officially ending the emergency use of three COVID-19 antibody tests made by Beckman Coulter, effective January 8, 2025. This change affects anyone using these specific tests for COVID-19 detection and diagnosis. The company requested this revocation, so no extra costs or disruptions are expected for users.
Next: 2025-04713, Welding, Cutting, and Brazing Standard; Extension of the Office of Management and Budget's (OMB) Approval of Information Collection (Paperwork) Requirements
OSHA is asking for public feedback to keep the paperwork rules for welding, cutting, and brazing safe and clear. This affects employers who follow these safety standards, with no new costs or big changes—just an extension of current rules. Comments are due by May 19, 2025, so don’t miss your chance to speak up!